CU71 – Alzheimer's Disease
Therapeutic Mechanism of CU71 in Alzheimer's Disease
CU71, a BBB stabilizer, improves cognition bt restoring barrier function and reducting neuroinflammation in AD
Alzheimer's Disease: The Central Role of BBB and Neuroinflammation
Next-generation Neurovascular Stabilizer
An oral candidate targeting BBB dysfunction and neuroinflammation
Preclinical evidence
Reduced BBB leakage & neuroinflammation, improved memory, partial β-amyloid reduction
Mechanistic differentiation
Focuses on neurovascular stabilization, complementing anti-amyloid mAbs and potentially reducing ARIA risk
Broader applicability
Potential not only in AD but also in cerebral small vessel disease and vascular dementia
Commercial value
Oral, multi-target profile enhances accessibility and cost-effectiveness, providing distinct competitiveness vs. anti-amyloid therapies